0001654954-22-011091.txt : 20220811
0001654954-22-011091.hdr.sgml : 20220811
20220811204656
ACCESSION NUMBER: 0001654954-22-011091
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220809
FILED AS OF DATE: 20220811
DATE AS OF CHANGE: 20220811
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AINOS INC
CENTRAL INDEX KEY: 0001859309
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41461
FILM NUMBER: 221157511
BUSINESS ADDRESS:
STREET 1: 8880 RIO SAN DIEGO DRIVE
STREET 2: SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
BUSINESS PHONE: 213005220
MAIL ADDRESS:
STREET 1: 8880 RIO SAN DIEGO DRIVE
STREET 2: SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ainos, Inc.
CENTRAL INDEX KEY: 0001014763
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 751974352
STATE OF INCORPORATION: TX
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: AINOS, INC.
STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
BUSINESS PHONE: 858-869-2986
MAIL ADDRESS:
STREET 1: AINOS, INC.
STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
FORMER COMPANY:
FORMER CONFORMED NAME: AMARILLO BIOSCIENCES INC
DATE OF NAME CHANGE: 19960516
4
1
section16.xml
PRIMARY DOCUMENT
X0306
4
2022-08-09
0001014763
Ainos, Inc.
AIMD
0001859309
AINOS INC
14F., NO. 61, SEC. 4
NEW TAIPEI BOULEVARD, XINZHUANG DISTRICT
NEW TAIPEI CITY
F5
242
TAIWAN
true
COMMON STOCK
2022-08-09
4
A
false
7647058
3.40
A
12311763
D
COMMON STOCK
2022-08-09
4
A
false
1014319
.20
A
13326082
D
Prior to the Reverse Split discussed herein the Reporting Person beneficially owned 69,970,571 common stock of the Issuer and after the Reverse Split, and prior to the present issuances, 4,664,705 common stock. The amounts of securities beneficially owned in column 5 of this report is calculated from a post-split baseline of 4,664,705.
Reference is made to that certain non-interest bearing Convertible Note in the principal amount of $26,000,000 issued to the Reporting Person as consideration under an Asset Purchase Agreement with the Issuer ("APA Note"). The APA Note is payable by January 30, 2027 unless converted immediately prior to the closing of a public offering and listing on a U.S. stock exchange at 80% of the initial public offering price ("Offering"). On 08/11/22, the Company completed a public offering at a $4.25 per unit price ("Offering") and a 15-for-1 reverse stock split on 08/08/22 ("Reverse Split"). Transaction reflects an acquisition price of $3.40 per share (80% of the Offering) and the issued shares give effect to the Reverse Split.
Reference is made to that certain Convertible Note in the principal amount of $3,000,000 bearing 1.85% interest per annum payable on February 28, 2023 and issued to the Reporting Person as consideration for working capital advances made to the Issuer ("Capital Note"). As of the conversion date, the Capital Note accrued $42,959 in interest and was converted at a $0.20 conversion rate pursuant to the Capital Note. The transaction gives effect to the Reverse Split noted in Footnote 1 above.
/s/ John Junyong Lee POA for Chun-Hsien Tsai, Chief Executive Officer
2022-08-11